Healthcare Industry News: Cefepime
News Release - May 11, 2010
FDA Approves Cefepime for Use In B. Braun's DUPLEX(R) SystemCompany Meets Customer Demands for Safe, Accurate and Efficient Drug Delivery By Expanding Offering of Cephalosporins Available in Ready-to-Use System
BETHLEHEM, Pa., May 11 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration recently approved an application that permits B. Braun Medical Inc. (B. Braun) to deliver FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun's DUPLEX® Drug Delivery System.
Used in hospitals and healthcare centers to treat a wide variety of bacterial infections, Cefepime should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in the treatment of pneumonia, uncomplicated and complicated urinary tract infections, empiric therapy for febrile neutropenic patients, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. The availability of 1g and 2g Cefepime in the DUPLEX® System will mean faster, safer and accurate administration of Cefepime to patients as it can be stored ready-to-use in a container wherever and whenever it is needed.
"Making 1g and 2g Cefepime available to healthcare workers in B. Braun's DUPLEX® Drug Delivery System gives them another weapon to combat challenging infections with speed, safety and accuracy," said Rob Albert, Vice President of Marketing for B. Braun Medical Inc.
The DUPLEX® Drug Delivery System is a ready-to-use, two-compartment, flexible, eco-friendly IV container that stores pre-measured pharmaceuticals and diluent doses. DUPLEX® is easy to stock as it can be stored at room temperature, with 18-month minimum dating, and fits in automated medication dispensing systems. Unit dose-based DUPLEX® helps healthcare facilities achieve Joint Commission and USP Chapter < 797 > compliance that improves the practice of healthcare professionals while advancing patient safety.
Healthcare workers administering 1g or 2g Cefepime through DUPLEX® simply fold and squeeze the container and shake it to mix the pharmaceuticals and diluent. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.
Customers interested in obtaining more information can call: 1-888-422-7286 (1-888-4BBRAUN).
About B. Braun
B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.
Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at email@example.com or visit B. Braun at www.bbraunusa.com.
Source: B. Braun Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.